文献速递新发突发、热带与寄生虫病

MAM01单克隆抗体预防疟疾的首次人体1期剂量递增试验

Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial.
PubMed 文献 · Lancet Infect Dis · 2025-09-23

在美国马里兰大学开展的1期双盲安慰剂对照适应性试验中,37名无疟疾感染史的成人随机接受MAM01单抗或安慰剂,MAM01耐受良好,40 mg/kg静脉组3人均未出现疟原虫血症,血清浓度>88 μg/mL与保护相关。

要点

  • MAM01单抗在1期试验中耐受良好,无治疗相关严重不良事件。
  • 40 mg/kg静脉组3名受试者在受控疟疾感染后均未出现疟原虫血症。
  • 血清MAM01浓度>88 μg/mL与抵御疟疾挑战相关。

核心结论

  • MAM01单抗耐受良好,达到安全性目标,并在无疟疾感染史的成人中通过受控人类疟疾感染模型显示出保护作用。

研究设计与样本

  • 1期、剂量递增、双盲、安慰剂对照、适应性试验,在美国马里兰大学疫苗开发与全球健康中心进行。
  • 受试者在给药后18-26周接受受控人类疟疾感染,通过五只感染NF54株的蚊虫叮咬。
  • 主要结局为各剂量水平及第二剂后MAM01的安全性和耐受性;次要结局包括药代动力学和保护效力。

主要发现

  • 2023年8月14日至2024年12月13日期间,63人评估资格,38人入组,37人随机分组。
  • MAM01给药耐受良好,单次或两次给药后无治疗相关严重不良事件。
  • 受控人类疟疾感染后,对照组6/6和MAM01组18/22出现疟原虫血症。
  • 40 mg/kg静脉剂量组3名受试者均未出现疟原虫血症。
  • 药代动力学分析显示,血清MAM01浓度>88 μg/mL可抵御疟疾挑战。

关键数值与推荐

  • 保护相关血清MAM01浓度阈值为>88 μg/mL。
  • 受控人类疟疾感染在给药后18-26周进行。

临床怎么用

  • MAM01在无疟疾感染成人中显示出保护概念验证,支持进一步开发用于疟疾预防。
  • 血清浓度>88 μg/mL可能作为保护相关的药代动力学目标,但需进一步验证。
  • 降低生产成本和选择目标人群中的合适剂量将决定疟疾单抗部署的可行性。

局限性

  • 样本量小,各剂量组仅3-6人,保护效力估计不精确。
  • 受控人类疟疾感染模型不能完全代表自然暴露,保护持续时间需进一步研究。
  • 试验仅在无疟疾感染史的美国成人中进行,结论外推至疟疾流行区人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malaria remains a leading cause of mortality among children in Africa, and recent advances in control have stagnated. Although new vaccines are available, protective efficacy is not optimum. Monoclonal antibodies targeting the Plasmodium falciparum circumsporozoite protein have potential to simplify prevention. We assessed the safety, pharmacokinetics, and protective efficacy of MAM01, a monoclonal antibody preferentially directed against the conserved Asn-Ala-Asn-Pro (NANP) central repeat region of circumsporozoite protein. METHODS: This phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial was done at the Center for Vaccine Development and Global Health, University of Maryland, Baltimore, MD, USA. Adults aged 18-50 years, with no previous malaria vaccinations or infections, and BMI of 18-30 kg/m2, were recruited sequentially, assigned to dose cohorts, and randomly assigned to receive the monoclonal antibody MAM01 (at 1·5, 5, 10, or 40 mg/kg intravenously or 5 mg/kg subcutaneously) or to placebo (identical buffer solution), with dose escalation staggered by 2-week intervals. Randomisation was done using an interactive response technology system. Participants and investigators were masked to treatment assignments. An untreated infectivity control was enrolled to support evaluation of protective efficacy. Participants from the MAM01 and control groups underwent controlled human malaria infection via the bites of five mosquitoes infected with P falciparum NF54 strain 18-26 weeks after monoclonal antibody or placebo administration. After malaria challenge, participants were followed up daily for ultra-sensitive PCR-based malaria detection on days 6-17, with continued follow-up of participants remaining aparasitaemic on days 20, 23, and 27. Participants who tested positive were treated with atovaquone-proguanil or artemether-lumefantrine; those who remained negative were empirically treated at day 27. A second dose of 5 mg/kg subcutaneously was administered to the cohorts that received 5 mg/kg subcutaneously or intravenously 2-4 weeks after completion of the controlled human malaria infection. The primary outcome was safety and tolerability of MAM01 at each dose level, and after second MAM01 dosing. Secondary outcomes included pharmacokinetic properties and protective efficacy (ie, presence of confirmed parasitaemia) after controlled human malaria infection. Safety was assessed in all participants who received trial intervention (MAM01 or placebo), as well as in participants who underwent controlled human malaria infection. This trial is complete and is registered with ClinicalTrials.gov, NCT05891236. FINDINGS: Between Aug 14, 2023, and Dec 13, 2024, 63 participants were assessed for eligibility, 38 were enrolled, and 37 were randomly assigned. After review of sentinel group safety data (1·5 mg/kg [n=1] and placebo [n=1]), 29 participants were assigned to receive MAM01 at doses of 1·5 mg/kg (n=5), 5 mg/kg (n=6), 10 mg/kg (n=6), or 40 mg/kg (n=6) intravenously or 5 mg/kg subcutaneously (n=6) and six were assigned to the placebo group. One participant was included as an untreated infectivity control. MAM01 administration was well tolerated. No treatment-related serious adverse events occurred after one or two doses. After controlled human malaria infection, six of six participants in the control group and 18 of 22 participants in the MAM01 group developed parasitaemia. None of three participants in the 40 mg/kg intravenous dose group developed parasitaemia. Pharmacokinetic analysis showed that serum MAM01 concentrations greater than 88 μg/mL protected against malaria challenge. INTERPRETATION: MAM01 was well tolerated, met safety targets, and showed clinical proof-of-principle by eliciting protection in malaria-naive adults using the controlled human malaria infection model. Progress driving down the cost of goods coupled with dose selection within target populations will dictate the feasibility of malaria monoclonal antibody deployment. FUNDING: Gates Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lyke KE, Berry AA, Laurens MB, et al. Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial. Lancet Infect Dis. 2025. PMID: 41005346. doi:10.1016/S1473-3099(25)00481-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。